LLY · 10-Q · 2026Q3 · Full report

Guidance and Outlook

ELI LILLY & Co · 2026-10-29 · Importance 32 · Surprise 24

Lilly expects near-term financial performance to be affected by the timing of potential additional regulatory approvals for orforglipron and by demand and uptake in new incretin channels and markets. It specifically identifies U.S. Medicare access for Zepbound and Foundayo as a factor, while noting that incretin volume fluctuations from channel dynamics or demand can disproportionately affect results in a period. Longer-term growth depends on sustaining the competitive position of its cardiometabolic portfolio and delivering further innovations with sufficient value.

Key facts

• Lilly has agreed in voluntary agreements with the U.S. government to lower Medicaid and certain other drug prices for U.S. patients and launch new medicines with a more balanced pricing approach across developed nations. source
• Lilly expects near-term financial performance to be affected by the timing of potential additional orforglipron regulatory approvals and by demand and uptake in new incretin channels and markets, including U.S. Medicare for Zepbound and Foundayo. source
• Lilly says incretin volume fluctuations due to channel dynamics or demand can have a disproportionate impact on results of operations in any given period. source
• The longer-term durability of Lilly's cardiometabolic offerings and sustainability of growth depend on maintaining or strengthening its competitive position and delivering further innovations with sufficient value. source
• Lilly warns that U.S. pricing arrangements and efforts to align domestic pharmaceutical prices with international benchmarks could negatively affect pricing strategies, product demand or access, or competitive positioning and may reduce revenue in certain markets. source